CAS 475108-18-0 appears in our catalog under these names: Tivozanib, >95% (HPLC), Tivozanib/ 98.23% (existing batch purity), Tivozanib (AV–951), Tivozanib, 98.00%, Tivozanib. Offered by: TRC, TargetMol, GLPBio, Chemat, Biosynth. Available pack sizes: 10mg, 50mg, 2mg, 5mg, 25mg, 100mg, 200mg, 10mM (in 1ml dmso).
Tivozanib is a member of the class of quinolines that is 6,7-dimethoxyquinoline substituted by a 3-chloro-4-{[(5-methyl-1,2-oxazol-3-yl)carbamoyl]amino}phenoxy group at position 4. It is a potent and selective inhibitor of VEGF receptor tyrosine kinases and was previously in clinical development for the treatment of metastatic renal cell carcinoma. It has a role as an antineoplastic agent, a vascular endothelial growth factor receptor antagonist and an apoptosis inducer. It is a member of phenylureas, a member of quinolines, an aromatic ether, a member of isoxazoles and a member of monochlorobenzenes.
Source: ChEBI
| Molecular formula | C22H19ClN4O5 |
|---|---|
| Molecular weight | 454.9 g/mol |
| IUPAC name | 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea |
| InChIKey | SPMVMDHWKHCIDT-UHFFFAOYSA-N |
| SMILES | CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl |
Computed by PubChem (NCBI)